Effect of dabigatran on referrals to and switching from warfarin in two academic anticoagulation management services

American Journal of Cardiology

Volumn 112, Issue 3, 2013, Pages 387-389

  Atay, Julie K ^a   Fanikos, John ^a   Barnes, Geoffrey D ^b   Ehle, Michael ^a   Coatney, John ^c   Piazza, Gregory ^a   Froehlich, James B ^b   Goldhaber, Samuel Z ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; WARFARIN;

AGED; ANTICOAGULATION; ARTICLE; CHADS2 SCORE; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG SUBSTITUTION; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NONVALVULAR HEART ATRIUM FIBRILLATION; PATIENT REFERRAL; PRIORITY JOURNAL; TREATMENT DURATION; VASCULAR DISEASE; VISUAL ANALOG SCALE;

ACADEMIC MEDICAL CENTERS; AGED; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DRUG APPROVAL; DRUG SUBSTITUTION; FEMALE; HUMANS; MALE; REFERRAL AND CONSULTATION; STROKE; UNITED STATES; WARFARIN;

EID: 84880329699     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.03.046     Document Type: Article

References (13)

1. D. Garcia, E. Libby, and M.A. Crowther The new oral anticoagulants Blood 115 2010 15 20
2. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P.A. Reilly, E. Themeles, J. Varrone, S. Wang, M. Alings, D. Xavier, J. Zhu, R. Diaz, B.S. Lewis, H. Darius, H.C. Diener, C.D. Joyner, L. Wallentin RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
3. N.E. Schwartz, and G.W. Albers Dabigatran challenges warfarin's superiority for stroke prevention in atrial fibrillation Stroke 41 2010 1307 1309
4. J. Ansell New oral anticoagulants should not be used as first line agents to prevent thromboembolism in patients with atrial fibrillation Circulation 125 2012 165 170
5. United States Food and Drug Administration. Pradaxa (Dabigatran Etexilate Mesylate): Drug Safety Communication - Safety Review of Post-Market Reports of Serious Bleeding Events. Available at: http://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm. Accessed on November 13, 2012.
6. B.N. Beasley, E.F. Unger, and R. Temple Anticoagulant options-why the FDA approved a higher but not a lower dose of dabigatran N Engl J Med 364 2011 1788 1790
7. E.S. Eerenberg, P.W. Kamphuisen, M.K. Sijpkens, J.C. Meijers, H.R. Buller, and M. Levi Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate Circulation 124 2011 1573 1579
8. K. Uchino, and A.V. Hernandez Dabigatran associated with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials Arch Intern Med 172 2012 397 402
9. J.S. Kim, F. She, K. Jongnarangsin, A. Chugh, R. Latchamsetty, H. Ghanbari, T. Crawford, M. Sinno, T. Carrigan, R. Kennedy, W. Saint-Phard, M. Yokokawa, E. Good, F. Bogun, F. Pelosi Jr., F. Morady, and H. Oral Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation Heart Rhythm 10 2013 483 489
10. L. Osterberg, and T. Blaschke Adherence to medication N Engl J Med 353 2005 487 497
11. J.V. Freeman, R.P. Zhu, D.K. Owens, A.M. Garber, D.W. Hutton, A.S. Go, P.J. Wang, and P.T. Turakhia Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation Ann Intern Med 154 2011 1 11
12. J.K. Atay, K. Fiumara, G. Piazza, J. Fanikos, and S.Z. Goldhaber Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation management service Clin Appl Thromb Hemost 18 2012 181 184
13. H.E. Bloomfield, A. Krause, N. Greer, B.C. Taylor, R. Macdonald, I. Rutks, P. Reddy, and T.J. Wilt Meta-analysis: effect of patient self-testing and self-management of long term anticoagulation on major clinical outcomes Ann Intern Med 154 2011 472 482